Mirdametinib Crystalline Complexes for Stable Pharmaceutical Processing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional solid state forms of Mirdametinib, including solvates and complexes, to improve processing, handling, stability, and bioavailability for the treatment of various cancers and neurofibromatosis.
Innovation Solution
Development of solid state forms, particularly crystalline complexes of Mirdametinib, such as Mirdametinib oxalic acid co-crystal Form A, characterized by specific XRPD, 13C NMR, and FTIR patterns, which are stable and suitable for pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If additional solid state forms and complexes of Mirdametinib are developed, then stability and bioavailability are improved, but device complexity and manufacturing complexity increase
Solution Approach 1:
The patent applies parameter changes by developing different solid state forms (polymorphs) and complexes of Mirdametinib with varying physical and chemical properties. Each form represents a different crystalline structure or molecular arrangement that provides improved stability, solubility, or bioavailability characteristics while maintaining the same active pharmaceutical ingredient identity.
Solution Approach 2:
The patent employs composite materials by creating complexes between Mirdametinib and various counterions or co-crystal partners. These composite structures combine the active ingredient with other crystalline materials to achieve desired pharmacological properties, such as improved dissolution profiles or enhanced stability, while forming new crystalline entities with characteristic XRD patterns.
2Reliability
If additional solid state forms and complexes of Mirdametinib are developed, then bioavailability and solubility are improved, but manufacturing precision and processing difficulty increase
Solution Approach 1:
The patent utilizes parameter changes by systematically varying crystallization conditions, pH levels, temperature profiles, and counterion selections to generate solid state forms with optimized bioavailability and solubility. Each form is characterized by specific physical parameters that can be controlled during manufacturing to achieve desired pharmacokinetic profiles.
Solution Approach 2:
The patent employs intermediary substances such as counterions, co-crystal partners, and formulation excipients that facilitate the formation of specific solid state forms. These intermediaries act as mediators during the crystallization process, guiding the formation of desired polymorphic forms or complexes that enhance bioavailability while managing processing complexity through controlled interaction mechanisms.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline complexes provide improved stability, solubility, and handling characteristics, enabling effective pharmaceutical formulations for treating conditions like Neurofibromatosis Type 1 Associated Plexiform Neurofibromas, low-grade gliomas, and various cancers.
Implementation Method 1
One or more of these techniques may be used to distinguish different polymorphic forms of a compound... characteristic X-ray powder diffraction pattern
Implementation Method 2
infrared absorption fingerprint
Implementation Method 3
solid state (13C) NMR spectrum
Implementation Method 4
thermal behaviors (e.g., measured by thermogravimetric analysis ("TGA"), or differential scanning calorimetry ("DSC"))
Implementation Method 5
thermal behaviors (e.g., measured by thermogravimetric analysis ("TGA"), or differential scanning calorimetry ("DSC"))
Implementation Method 6
crystalline forms I, II and IV of Mirdametinib... crystalline form IV of Mirdametinib which is essentially pure
Implementation Method 7
polymorphism, the occurrence of different crystalline forms, is a property of some molecules and molecular complexes
Data Source
AI summary
The present disclosure encompasses solid state forms of Mirdametinib, particularly to Mirdametinib complexes. In embodiments the present disclosure encompasses processes for preparation thereof, and pharmaceutical compositions thereof.